247 related articles for article (PubMed ID: 25983054)
41. On-treatment monitoring of adefovir therapy in chronic hepatitis B: virologic response can be assessed at 24 weeks.
Reijnders JG; Leemans WF; Hansen BE; Pas SD; de Man RA; Schutten M; Janssen HL
J Viral Hepat; 2009 Feb; 16(2):113-20. PubMed ID: 19175883
[TBL] [Abstract][Full Text] [Related]
42. Adefovir for chronic hepatitis B treatment: identification of virological markers linked to therapy response.
Rodriguez-Frias F; Jardi R; Schaper M; Buti M; Ferrer-Costa C; Tabernero D; Homs M; Esteban R
Antivir Ther; 2008; 13(8):991-9. PubMed ID: 19195324
[TBL] [Abstract][Full Text] [Related]
43. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2).
Osiowy C; Villeneuve JP; Heathcote EJ; Giles E; Borlang J
J Clin Microbiol; 2006 Jun; 44(6):1994-7. PubMed ID: 16757589
[TBL] [Abstract][Full Text] [Related]
44. Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen.
Svarovskaia ES; Curtis M; Zhu Y; Borroto-Esoda K; Miller MD; Berg T; Lavocat F; Zoulim F; Kitrinos KM
J Viral Hepat; 2013 Feb; 20(2):131-40. PubMed ID: 23301548
[TBL] [Abstract][Full Text] [Related]
45. [Efficacy of the 96-week adefovir dipivoxil therapy in patients with chronic hepatitis B].
Xu Z; Chen LB; Cao H; Shu X; Xu QH; Li G; Xie QF
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2010 Jun; 24(3):224-6. PubMed ID: 21186534
[TBL] [Abstract][Full Text] [Related]
46. [Resistance mutation patterns of hepatitis B virus in patients with suboptimal response to adefovir dipivoxil therapy after lamivudine resistance].
Wu ZP; Hang T; Gao YT; Li Y; Liu T; Jing L; Liu L; Du Z
Zhonghua Gan Zang Bing Za Zhi; 2010 Jul; 18(7):498-501. PubMed ID: 20678438
[TBL] [Abstract][Full Text] [Related]
47. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
[TBL] [Abstract][Full Text] [Related]
48. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
[TBL] [Abstract][Full Text] [Related]
49. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
50. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.
Westland CE; Yang H; Delaney WE; Gibbs CS; Miller MD; Wulfsohn M; Fry J; Brosgart CL; Xiong S;
Hepatology; 2003 Jul; 38(1):96-103. PubMed ID: 12829991
[TBL] [Abstract][Full Text] [Related]
51. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.
Choe WH; Hong SP; Kim BK; Ko SY; Jung YK; Kim JH; Yeon JE; Byun KS; Kim KH; Ji SI; Kim SO; Lee CH; Kwon SY
Antivir Ther; 2009; 14(7):985-93. PubMed ID: 19918102
[TBL] [Abstract][Full Text] [Related]
52. Resistant mutants induced by adefovir dipivoxil in hepatitis B virus isolates.
Jiang SW; Yao LP; Hu AR; Hu YR; Chen SX; Xiong T; Gao GS; Liang XY; Ding SX; Weng PJ
World J Gastroenterol; 2014 Dec; 20(45):17100-6. PubMed ID: 25493022
[TBL] [Abstract][Full Text] [Related]
53. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
Chen CH; Wang JH; Lu SN; Hu TH; Hung CH; Chang MH; Changchien CS; Lee CM
Antivir Ther; 2012; 17(4):701-9. PubMed ID: 22358132
[TBL] [Abstract][Full Text] [Related]
54. The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil.
Liu Y; Li X; Xin S; Xu Z; Chen R; Yang J; Liu L; Wong VW; Yang D; Chan HL; Xu D
J Viral Hepat; 2015 Mar; 22(3):328-34. PubMed ID: 25132017
[TBL] [Abstract][Full Text] [Related]
55. Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing.
Rodriguez C; Chevaliez S; Bensadoun P; Pawlotsky JM
Hepatology; 2013 Sep; 58(3):890-901. PubMed ID: 23505208
[TBL] [Abstract][Full Text] [Related]
56. Deep sequencing analysis of HBV genotype shift and correlation with antiviral efficiency during adefovir dipivoxil therapy.
Wang Y; Shan X; Liang Z; Shan Y; Huang W; Zhang D; Zen A; Zhou X; Zhao Y; Gong X; Xu G; Zhang X; Chen J; Huang A
PLoS One; 2015; 10(6):e0131337. PubMed ID: 26110616
[TBL] [Abstract][Full Text] [Related]
57. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection.
Berg T; Marcellin P; Zoulim F; Moller B; Trinh H; Chan S; Suarez E; Lavocat F; Snow-Lampart A; Frederick D; Sorbel J; Borroto-Esoda K; Oldach D; Rousseau F
Gastroenterology; 2010 Oct; 139(4):1207-17. PubMed ID: 20600025
[TBL] [Abstract][Full Text] [Related]
58. Adefovir and lamivudine combination therapy in patients with entecavir-resistant chronic hepatitis B: antiviral responses and evolution of mutations.
Yim HJ; Lee HJ; Suh SJ; Seo YS; Kim CW; Lee CD; Park SH; Lee MS; Park CK; Chae HB; Kim MY; Baik SK; Kim YS; Kim JH; Lee JI; Lee JW; Hong SP; Um SH
Intervirology; 2014; 57(5):239-47. PubMed ID: 24993731
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment.
Wang X; Zhang C; Zhu Y; Xiong Y; Wang Y
Antiviral Res; 2014 Mar; 103():71-7. PubMed ID: 24462954
[TBL] [Abstract][Full Text] [Related]
60. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
